

Substitute for form 1449A/PTO and/or 1449B/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Complete if Known

Application Number	10/780,391
Filing Date	February 17, 2004
First Named Inventor	Wiemer
Group Art Unit	1626
Examiner Name	Kamal A Saeed

Sheet 1 of 1

Attorney Docket No: 17023.056US2

US PATENT DOCUMENTS

Examiner Initials *	US Document Number	Publication Date	Name of Patentee/Applicant of Document
NG	6,727,234	April 27, 2004	Wiemer et al.

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document Number (include country code)	Publication Date	Translation (Abstract Only or Full Translation, if applicable)

OTHER DOCUMENTS – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Include last name of the first author (in CAPITAL letters), "Title of the Article", Title of the Source (book, magazine, journal, serial, symposium, catalog, etc.), Volume-Number, page(s) and (date).

/Nyeemah Grazier/

01/05/2007

EXAMINER

DATE CONSIDERED

Substitute Information Disclosure Statement Form (PTO-1449)

* Examiner: Initial if document considered, whether or not the citation is in conformance with MPEP 609. Draw line through citation if not considered. Include copy of this form with next communication to Applicant.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td colspan="2" style="text-align: center;"><i>Complete if Known</i></td> </tr> <tr> <td style="width: 50%;">Application Number</td> <td>Unknown</td> </tr> <tr> <td>Filing Date</td> <td>Even Date Herewith</td> </tr> <tr> <td>First Named Inventor</td> <td>Wiemer, David</td> </tr> <tr> <td>Group Art Unit</td> <td>Unknown</td> </tr> <tr> <td>Examiner Name</td> <td>Unknown</td> </tr> </table>	<i>Complete if Known</i>		Application Number	Unknown	Filing Date	Even Date Herewith	First Named Inventor	Wiemer, David	Group Art Unit	Unknown	Examiner Name	Unknown
<i>Complete if Known</i>													
Application Number	Unknown												
Filing Date	Even Date Herewith												
First Named Inventor	Wiemer, David												
Group Art Unit	Unknown												
Examiner Name	Unknown												
Sheet 1 of 5	Attorney Docket No: 875.050US2												

US PATENT DOCUMENTS						
Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date If Appropriate
NG	US-5,574,025	11/12/1996	Anthony, N J., et al.	514	129	10/26/1994

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	T ²

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁴
NG		ADJEI, A A., et al., "A Phase I Trial of the Farnesyl Transferase Inhibitor SCH66336: Evidence for Biological and Clinical Activity", <u>Cancer Research</u> , Vol. 60,(April 1, 2000),pp. 1871-1877	
NG		ASHAR, H R., et al., "Farnesyl Transferase Inhibitors Block the Farnesylation of CENP-E and CENP-F and Alter the Association of CENP-E with the Microtubules", <u>The Journal of Biological Chemistry</u> , Vol. 275, No. 39,(September 29, 2000),pp. 30451-30457	
NG		BERGO, M O., et al., "Targeted Inactivation of the Isoprenylcysteine Carboxyl Methyltransferase Gene Causes Mislocalization of K-Ras in Mammalian Cells", <u>The Journal of Biological Chemistry</u> , Vol. 275, No. 23,(2000),pp. 17605-17610	
NG		CASEY, P J., et al., "Enzymatic modification of proteins with a geranylgeranyl isoprenoid", <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 88,(October, 1991),pp. 8631-8635	
NG		CERMAK, D M., et al., "2-(Acyloxy)ethylphosphonate Analogues of Prenyl Pyrophosphates: Synthesis and Biological Characterization", <u>Bioorganic & Medicinal Chemistry</u> , Vol. 8,(2000),2729-2737	
NG		CERMAK, D M., et al., "Synthesis of Nonracemic Dimethyl Alpha-(Hydroxyfarnesyl)phosphonates via Oxidation of Dimethyl Farnesylphosphonate with (Camphorsulfonyl)oxaziridines", <u>J. Org. Chem.</u> , Vol. 64, No. 2,(1999),pp. 388-393	
NG		CHANG, JEN-WEN A., et al., "Stereochemical Effects on the Conformation and Kinetics of Nucleophilic Displacement Reactions in Epimeric Six-membered Ring Phosphonate Diesters", <u>Tetrahedron</u> , Vol. 43, No. 22,(1987),pp. 5187-5196	
NG		CHEHADE, K A., et al., "Design and Synthesis of a Transferable Farnesyl Pyrophosphate Analogue to Ras by Protein Farnesyltransferase", <u>J. Org. Chem.</u> , Vol. 65, No. 10,(2000),pp. 3027-3033	

EXAMINER

/Nyeemah Grazier/

DATE CONSIDERED

01/05/2007

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>	Complete if Known	
	Application Number	Unknown
	Filing Date	Even Date Herewith
	First Named Inventor	Wiemer, David
	Group Art Unit	Unknown
	Examiner Name	Unknown
Sheet 2 of 5	Attorney Docket No: 875.050US2	

NG		CHEN, Z , et al., "Both Farnesylated and Geranylgeranylated RhoB Inhibit Malignant Transformation and Suppress Human Tumor Growth in Nude Mice", <u>The Journal of Biological Chemistry</u> , Vol. 275, No. 24,(June 16, 2000),pp. 17974-17978	
NG		DAVISSON, V J., et al., "Phosphorylation of Isoprenoid Alcohols", <u>J. Org. Chem.</u> , Vol. 51, No. 25,(1986),pp. 4768-4779	
NG		DING, C Z., et al., "Discovery and Structure-Activity Relationships of Imidazole-Containing Tetrahydrobenzodiazepine Inhibitors of Farnesyltransferase", <u>J. Med. Chem.</u> , Vol. 42, No. 25,(1999),pp. 5241-5253	
NG		DU, W , et al., "Geranylgeranylated RhoB Mediates Suppression of Human Tumor Cell Growth by Farnesyltransferase Inhibitors", <u>Cancer Research</u> , Vol. 59,(November 1, 1999),pp. 5492-5496	
NG		EDAMATSU, H , et al., "Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines", <u>Oncogene</u> , Vol. 19,(2000),pp. 3059-3068	
NG		EDELSTEIN, R L., et al., "Stereochemical Analysis of the Reaction Catalyzed by Yeast Protein Farnesyltransferase", <u>J. Org. Chem.</u> , Vol. 63, No. 16,(1998),pp. 5298-5299	
NG		FINDER, J D., et al., "Inhibition of Protein Geranylgeranylation Causes a Superinduction of Nitric-oxide Synthase-2 by Interleukin-1Beta in Vascular Smooth Muscle Cells", <u>The Journal of Biological Chemistry</u> , Vol. 272, No. 21,(May 23, 1997),pp. 13484-13488	
NG		FLINT, O R., et al., "HMG CoA Reductase Inhibitor-Induced Myotoxicity: Pravastatin and Lovastatin Inhibit the Geranylgeranylation of Low-Molecular-Weight Proteins in Neonatal Rat Muscle Cell Culture", <u>Toxicology and Applied Pharmacology</u> , Vol. 145,(1997),pp. 99-110	
NG		GALBIATI, F , et al., "The Dually Acylated NH2-terminal Domain of Gi1Alpha Is Sufficient to Target a Green Fluorescent Protein Reporter to Caveolin-enriched Plasma Membrane Domains", <u>the Journal of Biological Chemistry</u> , Vol. 274, No. 9,(February 26, 1999),pp. 5843-5850	
NG		GAON, I , "Photoactive Analogs of Farnesyl Pyrophosphate Containing Benzoylbenzoate Esters: Synthesis and Application to Photoaffinity Labeling of Yeast Protein Farnesyltransferase", <u>J. Org. Chem.</u> , Vol. 61, No. 22,(1996),pp. 7738-7745	
NG		GIBBS, R A., et al., "A Pd(0)-Catalyzed Route to 13-Methylidenefarnesyl Diphosphate", <u>Tetrahedron Letters</u> , Vol. 35, No. 16,(1994),pp. 2509-2512	
NG		GIBBS, B S., et al., "Novel Farnesol and Geranylgeranoil Analogues: A Potential New Class of Anticancer Agents Directed against Protein Prenylation", <u>J. Med. Chem.</u> , Vol. 42,(1999),pp. 3800-3808	
NG		GORENSTEIN, D G., "Stereochemical Effects in Biomolecules", <u>Chem. Rev.</u> , Vol. 87, No. 5,(1987),pp. 1047-1077	

EXAMINER

/Nyeemah Grazier/

DATE CONSIDERED

01/05/2007

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td colspan="2" style="text-align: center;"><i>Complete if Known</i></td> </tr> <tr> <td style="width: 50%;">Application Number</td> <td>Unknown</td> </tr> <tr> <td>Filing Date</td> <td>Even Date Herewith</td> </tr> <tr> <td>First Named Inventor</td> <td>Wiemer, David</td> </tr> <tr> <td>Group Art Unit</td> <td>Unknown</td> </tr> <tr> <td>Examiner Name</td> <td>Unknown</td> </tr> </table>	<i>Complete if Known</i>		Application Number	Unknown	Filing Date	Even Date Herewith	First Named Inventor	Wiemer, David	Group Art Unit	Unknown	Examiner Name	Unknown
<i>Complete if Known</i>													
Application Number	Unknown												
Filing Date	Even Date Herewith												
First Named Inventor	Wiemer, David												
Group Art Unit	Unknown												
Examiner Name	Unknown												
Sheet 3 of 5	Attorney Docket No: 875.050US2												

NG		HARTWIG, J F., et al., "Synthesis and DNA-Binding Properties of a Cisplatin Analogue Containing a Tethered Dansyl Group", <u>J. Am. chem. Soc.</u> , Vol. 114,(1992),pp. 8292-8293	
NG		HENRY, K J., et al., "Discovery of a Series of Cyclohexylethylamine-Containing Protein Farnesyltransferase Inhibitors Exhibiting Potent Cellular Activity", <u>J. Med. Chem.</u> , Vol. 42, No. 23,(1999),pp. 4844-4852	
NG		HOHL, R J., "Inhibition of Hydroxymethylglutaryl Coenzyme A Reductase Activity Induces a Paradoxical Increase in DNA Synthesis in Myeloid Leukemia Cells", <u>Blood</u> , Vol. 77, No. 5,(March 1, 1991),pp. 1064-1070	
NG		HOHL, R J., et al., "Stereochemistry-Dependent Inhibition of RAS Farnesylation by Farnesyl Phosphonic Acids", <u>Lipids</u> , Vol. 33, No. 1,(1998),pp. 39-46	
NG		HOLSTEIN, S A., et al., "Phosphonate and Bisphosphonate Analogues of Farnesyl Pyrophosphate as Potential Inhibitors of Farnesyl Protein Transferase", <u>Bbioorganic & Medicinal Chemistry</u> , Vol. 6,(1998),pp. 687-694	
NG		HUNT, J T., et al., "Discovery of (R)-7-Cyano-2,3,5,5-tetrahydro-1(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1, 4-benzodiazepine (BMS-214662), a Farnesyltransferase Inhibitor with Potent Preclinical Antitumor Activity", <u>Journal of Medicinal Chemistry</u> , Vol. 43, No. 20,(October 5, 2000),pp. 3587-3595	
NG		JIANG, K , et al., "The Phosphoinositide 3-OH Kinase/AKT2 Pathway as a Critical Target for Farnesyltransferase Inhibitor-Induced Apoptosis", <u>Molecular and Cellular Biology</u> , Vol. 20, No. 1,(January, 2000),pp. 139-148	
NG		KANG, M S., et al., "Farnesyl-Derived Inhibitors of Ras Farnesyl Transferase", <u>Biochemical and Biophysical Research Communications</u> , Vol. 217, No. 1,(1995),pp. 245-249	
NG		KARP, J E., et al., "Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase1 clinical-laboratory correlative trial", <u>Blood</u> , Vol. 97, No. 11,(June 1, 2001),pp. 3361-3369	
NG		LIU, AI-XUE , et al., "RhoB Alteration Is necessary for Apoptotic and Antineoplastic Responses to Farnesyltransferase Inhibitors", <u>Molecular and Cellular Biology</u> , Vol. 20, No. 16,(August 2000),pp. 6105-6113	
NG		LONG, S B., et al., "cocrystal Structure of Protein Farnesyltransferase Complexed with Farnesyl Diphosphate Substrate", <u>Biochemistry</u> , Vol. 37,(1998),pp. 9612-9618	
NG		LUCKMAN, S P., et al., "Nitrogen-containing Bisphosphonated Inhibit the Mevalonate Pathway and Prevent Post-Translational Prenylation of GTP-Binding Proteins, Including Ras", <u>Journal of Bone and Mineral Research</u> , Vol. 13, No. 4,(1998),pp. 581-589	
NG		MCCLARD, R W., et al., "Novel Phosphonylphosphinyl (P-C-P-C-) Analogues of Biochemically Interesting Diphosphates. Syntheses and Properties of P-C-P-C- Analogues of Isopentenyl Diphosphate and Dimethylallyl Diphosphate", <u>J. Am. Chem. Soc.</u> , Vol. 109,(1987),pp. 5544-5545	

EXAMINER

/Nyeemah Grazier/

DATE CONSIDERED

01/05/2007

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td colspan="2">Complete if Known</td> </tr> <tr> <td style="width: 50%;">Application Number</td> <td>Unknown</td> </tr> <tr> <td>Filing Date</td> <td>Even Date Herewith</td> </tr> <tr> <td>First Named Inventor</td> <td>Wiemer, David</td> </tr> <tr> <td>Group Art Unit</td> <td>Unknown</td> </tr> <tr> <td>Examiner Name</td> <td>Unknown</td> </tr> </table>	Complete if Known		Application Number	Unknown	Filing Date	Even Date Herewith	First Named Inventor	Wiemer, David	Group Art Unit	Unknown	Examiner Name	Unknown
Complete if Known													
Application Number	Unknown												
Filing Date	Even Date Herewith												
First Named Inventor	Wiemer, David												
Group Art Unit	Unknown												
Examiner Name	Unknown												
Sheet 4 of 5	Attorney Docket No: 875.050US2												

NG		MECHELKE, M F., et al., "Preparation of (2E,6E)-10,11-Dihydrofarnesol via a (Bisphenyl)dithioacetal Reduction", <u>Tetrahedron Letters</u> , Vol. 39,(1998),pp. 9609-9612	
NG		MECHELKE, M F., et al., "Synthesis of Farnesol Analogues through Cu(I)-Mediated Displacements of Allylic THP Ethers by Grignard Reagents", <u>J. Org. Chem.</u> , Vol. 64, No. 13,(1999),pp. 4821-4829	
NG		MOASSER, M M., et al., "Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones", <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 95,(February, 1998),pp. 1369-1374	
NG		MU, Y., "Cuprate-Mediated Synthesis and Biological Evaluation of Cyclopropyl- and tert-Butylfarnesyl Diphosphate Analogs", <u>J. Org. Chem.</u> , Vol. 61,(1996),pp. 8010-8015	
NG		MU, Y., et al., "On the Stereochemical Course of Human Protein-Farnesyl Transferase", <u>Journal of the American Chemical Society</u> , Vol. 118, No. 8,(February 28, 1996),pp. 1817-1823	
NG		OWEN, D J., et al., "Chemo-Enzymatic Synthesis of Fluorescent Rab 7 Proteins: Tools to Study Vesicular Trafficking in Cells", <u>Angew. Chem. Int. Ed.</u> , Vol. 38, No. 4,(1999),pp. 509-512	
NG		PATEL, D V., et al., "Farnesyl Diphosphate-Based Inhibitors of Ras Farnesyl Protein Transferase", <u>J. Med. Chem.</u> , Vol. 38,(1995),pp. 2906-2921	
NG		POMPLIANO, D L., et al., "Intramolecular Fluorescence Enhancement: A Continuous Assay of Ras Farnesyl:Protein Transferase", <u>J. Am. Chem. Soc.</u> , Vol. 114,(1992),pp. 7945-7946	
NG		POMPLIANO, D L., "Steady-State Kinetic Mechanism of Ras Farnesyl:Protein Transferase", <u>Biochemistry</u> , Vol. 31, No. 15,(1992),pp. 3800-3807	
NG		ROY, MARIE-ODILE, "Mutational and Biochemical Analysis of Plasma Membrane Targeting Mediated by the Farnesylated, Polybasic Carboxy Terminus of K-ras4B", <u>Biochemistry</u> , Vol. 39,(2000),pp. 8298-8307	
NG		SEPP-LORENZINO, L., et al., "A Peptidomimetic Inhibitor of Farnesyl:Protein Transferase Blocks the Anchorage-dependent and -independent Growth of Human Tumor Cell Lines", <u>Cancer Research</u> , Vol. 55,(November 15, 1995),pp. 5302-5309	
NG		SUN, J., et al., "Antitumor Efficacy of a Novel Class of Non-thiol-containing Peptidomimetic Inhibitors of Farnesyltransferase and Geranylgeranyltransferase I: Combination Therapy with the Cytotoxic Agents Cisplatin, Taxol, and Gemcitabine", <u>Cancer Research</u> , Vol. 59,(October 1, 1999),pp. 4919-4926	
NG		TAHIR, S K., et al., "Inhibition of farnesyltransferase with A-176120, a novel and potent farnesyl pyrophosphate analogue", <u>European Journal of Cancer</u> , Vol. 36,(2000),pp. 1161-1170	
NG		THURMOND, D C., et al., "Regulation of Insulin-stimulated GLUT4 Translocation by Munc18c in 3T3L1 Adipocytes", <u>The Journal of Biological Chemistry</u> , Vol. 273, No. 50,(1998),pp. 33876-33883	
NG		VALENTIJN, A.R.P.M., et al., "Synthesis of Pyrophosphonic Acid Analogues of Farnesyl Pyrophosphate", <u>Tetrahedron</u> , Vol. 51, No. 7,(1995),pp. 2099-2108	

EXAMINER

/Nyeemah Grazier/

DATE CONSIDERED

01/05/2007

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td colspan="2"><i>Complete if Known</i></td> </tr> <tr> <td style="width: 50%;">Application Number</td> <td>Unknown</td> </tr> <tr> <td>Filing Date</td> <td>Even Date Herewith</td> </tr> <tr> <td>First Named Inventor</td> <td>Wiemer, David</td> </tr> <tr> <td>Group Art Unit</td> <td>Unknown</td> </tr> <tr> <td>Examiner Name</td> <td>Unknown</td> </tr> </table>	<i>Complete if Known</i>		Application Number	Unknown	Filing Date	Even Date Herewith	First Named Inventor	Wiemer, David	Group Art Unit	Unknown	Examiner Name	Unknown
<i>Complete if Known</i>													
Application Number	Unknown												
Filing Date	Even Date Herewith												
First Named Inventor	Wiemer, David												
Group Art Unit	Unknown												
Examiner Name	Unknown												
Sheet 5 of 5	Attorney Docket No: 875.050US2												

NG		VAN BEEK, E , et al., "Farnesyl Pyrophosphate Synthase Is the Molecular Target of Nitrogen-Containing Bisphosphonates", <u>Biochemical and Biophysical research Communications</u> , Vol. 264, No. 1,(1999),pp. 108-111	
NG		YAMAMOTO, Y , et al., "The Dansyl Group as a Molecular Probe for the Histochemical Localization of a Synthetic Fibronectin-related Peptide", <u>Chemistry Letters</u> , (1994),pp. 1379-1382	
NG		ZAHN, T J., "Evaluation of Isoprenoid Conformation in Solution and in the Active Site of Protein-Farnesyl Transferase using Carbon-13 Labeling in Conjunction with Solution- and Solid-State NMR", <u>Journal of American Chemical Society</u> , Vol. 122, No. 30,(August 2, 2000),pp. 7153-7164	
NG		ZAHN, T J., et al., "Synthesis and Conformational Analysis of Di-13C-Labeled Farnesyl Diphosphate Analogs", <u>Tetrahedron Letters</u> , Vol. 39,(1998),pp. 3991-3994	
NG		ZUJEWSKI, J , et al., "Phase I and Pharmacokinetic Study of Farnesyl Protein Transferase Inhibitor R115777 in Advance Cancer", <u>Journal of Clinical Oncology</u> , Vol. 18, No. 4,(February, 2000),pp. 927-941	

EXAMINER

/Nyeemah Grazier/

DATE CONSIDERED

01/05/2007